We are proud to introduce our 2019 SynBioStars, take a look below at seven of the leading synthetic biology startups today. They all applied to be a part of our programme and have matched our criteria – being under five years old, having under 10 employees (full and part time) and at seed stage or earlier (not yet at Series A or beyond). They are all exhibiting and speaking at SynBio Markets (18-19 November, Berlin) and are all set for big futures. If you can’t attend, weblinks are attached to each of the listings below – they’d love to hear from you. And remember, when these companies go global – you heard about them here first!
Our differentiating strategy is to work in modular, proprietary and patent-protectable ways across every dimension (microorganisms, bioreactors, downstreaming processes). This platform allows for drastic cost, purity and sustainability advantages over traditional production methods.
For cannabinoids (e.g. CBD), we expect to achieve productivity advantages of 10x – 100x or more over the targets of the most promising biosynthetic methods currently in development. Beyond cannabinoids, Synbionik develops end-to-end production platforms for other high-value biochemicals, with similar productivity and cost advantages (10x-100x).
For more: www.synbionik.com
Tired of waiting for ordered DNA primers? Making your own primers becomes as convenient as brewing a nice cup of coffee, right at your desktop – Kilobaser is the Nespresso machine for DNA. In less than 90 minutes your DNA primer is produced fully automated and ready to use for PCR and other applications.
For more: www.kilobaser.com
Food contamination leads to illness, loss of consumer trust, expensive recalls, and lost product. Food and beverage companies cannot completely eliminate product recalls because current testing methods for contaminants are too slow.
Using advanced synthetic biology, we speed up the time to result for food safety testing by 10x, allowing customers to take immediate action to prevent brand damage.
We have completed a trial with a €2b+ food and beverage company and have two project contracts in negotiation to continue prototype development at our Berlin lab.
For more: www.miprobes.de
BioC3 is a synthetic biotech company founded in 2016, based in Toulouse, France. We have an exclusive patent on the microbial production of DHAP – Dihydroxyacetone phosphate, a building block that can be derived into several other molecules with numerous applications on cosmetic, pharmaceutical and agro-industry. Our solution brings this molecule and its derivatives with a better environmental impact, at a faster production pace and cheaper that the current production methods (chemical and enzymatic).
For more: www.bioC3.com
We have addressed the huge bottlenecks of low-throughput, high-cost and sustainability issues associated with applications of electrophoresis, purification/extraction and electrotransfection/electroporation in the biotechnology field.
Our technologies provide affordable solutions that accelerate the throughput and performance in synthetic biology and in the biotech industry providing sustainable microbial cell factories.
We have developed the following three technologies and protected them with two patent families:
1. high-throughput electrophoresis with online real-time analysis of DNA/RNA/proteins/amino acids/sugars
2. high-throughput sustainable purification of DNA/RNA/proteins/amino acids/sugars.
3. high-throughput sustainable electrotransfection and electro-extraction.
For more: www.accelerbiotics.com
Story: GEEN Biotechnology was founded in 2015. Our journey started by developing a synthetic viral plasmid, GeenOS, to run genetic circuits with maximum accuracy compared to their in silico design & simulations. Today we use a new version of the same genetic circuitry as the most powerful directed evolution technology designed to evolve therapeutic viruses with outstanding properties.
Mission: Our aim is to substitute conventional cancer therapies with a safer, personalization-friendly and a more effective alternative. We believe that this is only possible by unlocking the potential of the long-promised oncolytic virotherapy.
Technology: Oncolytic viruses are not naturally evolved as cancer therapeutics. Our approach is to redesign an evolutionary process for oncolytic viruses and transform their beneficial therapeutic side properties into their purposes.
Our technology comprises a piece of DNA where we define an engineered goal of evolution to the viruses and force them to learn how to activate a patient’s immune system against cancer without being recognized within the body.
For more: www.geenbio.com
SilicoLife designs optimised microorganisms and novel pathways for industrial biotechnology applications, based on artificial intelligence and synthetic biology approaches, shortening the development time and costs of new highly effective processes for the production of specific target compounds such as chemicals, food ingredients or biopolymers.
Silicolife combines the latest synthetic biology advances with proprietary state-of-the-art algorithms to find the most efficient pathways between raw-material and end-product, streamlining the strain design process and exploring non-intuitive pathway modifications, dramatically cutting down costs and reducing laboratory experimentation.
For more: www.silicolife.com
Want to meet these synthetic biology startups, and 150+ other industry figures, then tickets are still available for SynBio Markets 2019 – so book here today or risk missing out!
If you like the bio-economy news story and updates from synthetic biology startups you may also be interested in…